This article is more than 5 years old. Information may no longer be current.

Five clinical trial updates you may have missed

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Several pharmaceutical companies have provided updates this month on phase 2 or phase 3 trials.

HemOnc Today provides this overview of five clinical trial updates you may have missed.

• A phase 2 trial designed to evaluate ENMD-2076 (CASI Pharmaceuticals) for the treatment of fibrolamellar carcinoma met its stage 1 endpoint of objective response for nonfutility based on prespecified interim analysis criteria. Read more.
• The phase 3 AFFINITY trial, designed to evaluate custirsen (OGX-011, OncoGenex) in men with metastatic castrate-resistant prostate cancer whose disease progressed after docetaxel treatment, failed to meet its primary endpoint of OS. Read more.
• The addition of selumetinib (AstraZeneca) to docetaxel chemotherapy as second-line treatment failed to extend PFS in patients with KRAS mutation–positive, locally advanced or metastatic non–small cell lung cancer, according to results of the randomized phase 3 SELECT-1 trial. Read more.
• Nivolumab (Opdivo, Bristol-Myers Squibb) monotherapy failed to extend PFS in treatment-naive patients with advanced, PD-L1–positive non–small cell lung cancer. However, a separate trial designed to evaluate nivolumab in combination with ipilimumab (Yervoy, Bristol-Myers Squibb) as first-line treatment for the same patient population will continue. Read more.
• Brentuximab vedotin (Adcetris, Seattle Genetics) improved outcomes compared with standard therapies among patients with cutaneous T-cell lymphoma, according to results of the randomized phase 3 ALCANZA trial. Read more.